GlassScriptPhysician profile
Eitan Samuel Frankel
NPI 1659805620
$36,907.29
in general payments reported to CMS, 2019-2025
28 companies · $4,256 in 2025
The $4,256 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $47.73 · 2021: $483 · 2022: $2,584 · 2023: $22K · 2024: $7,736 · 2025: $4,256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $22K · Food and Beverage: $8,460 · Travel and Lodging: $3,085 · Education: $747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $21,500.00 |
| Food and Beverage | $8,459.83 |
| Travel and Lodging | $3,084.95 |
| Education | $747.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $24,017.91 | 2022-2025 | Micra, Cobalt Dr Mri Surescan, Aurora Ev-Icd Mri Surescan |
| Abbott Laboratories | $4,662.87 | 2020-2025 | Ensite Precision, Ensite, Thoratec Heartmate 3 Lvas Implant Kit |
| Boston Scientific Corporation | $3,004.22 | 2023-2025 | Watchman Flx, Versacross Access Solution, Farapulse |
| Atricure, INC. | $891.87 | 2023-2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Biotronik INC. | $562.45 | 2024 | |
| Amgen INC. | $424.20 | 2022-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $423.31 | 2021-2022 | |
| Biosense Webster, INC. | $422.41 | 2024-2025 | Carto 3, Nuvision Ice Catheter |
| Pfizer INC. | $406.02 | 2020-2025 | |
| Medical Device Business Services, INC. | $326.74 | 2023 | Carto 3 |
| Sanofi-Aventis U.S. LLC | $246.95 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $223.67 | 2022-2025 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $192.04 | 2023-2025 | Lifevest |
| Impulse Dynamics (USA) INC. | $180.01 | 2023-2024 | Optimizer, Optimizer |
| Novartis Pharmaceuticals Corporation | $168.50 | 2023-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiva Medical, INC. | $136.09 | 2023-2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Actelion Pharmaceuticals US, INC. | $106.71 | 2023-2024 | Opsumit, Uptravi |
| Novo Nordisk INC | $103.67 | 2022 | |
| Philips North America LLC | $98.56 | 2023 | |
| Janssen Pharmaceuticals, INC | $61.64 | 2023-2024 | Xarelto |
| Ethicon US, LLC | $58.81 | 2024-2025 | Surgicel Nu-Knit, Stratafix, Ethicon |
| Cardiovascular Systems INC. | $41.48 | 2021 | |
| Lantheus Medical Imaging, INC. | $35.02 | 2020-2021 | |
| Kestra Medical Technology Services, INC. | $29.77 | 2025 | Assure Wcd |
| Convatec INC. | $28.52 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.88 | 2024 | Jardiance |
| Inspire Medical Systems, INC. | $17.18 | 2024 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $16.79 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eitan Frankel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.